Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism is a research paper published in Oncotarget (2020). On theSindex it has a DataRank of 0. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH HHS
Grant: S10 OD021669
NCI NIH HHS
Grant: T32 CA009171
NCI NIH HHS
Grant: R50 CA221838
NIH HHS
Grant: S10 OD023658
NCI NIH HHS
Grant: P01 CA174439
NCI NIH HHS
Grant: R01 CA117830
NIH HHS
Grant: S10 OD023586
NCI NIH HHS
Grant: R01 CA186775
National Institutes of Health
Grant: 1S10OD023658-01
Purchase of a Seahorse Bioscience XF Analyzer
National Institutes of Health
Grant: 2R01CA117830-06
Regulation of KSHV Latency
National Institutes of Health
Grant: 5R01CA186775-03
Development of a Small Molecule Inhibitor for KSHV LANA
National Institutes of Health
Grant: 4P01CA174439-04
Early Events in KSVH Infection of Primary B-cells
National Institutes of Health
Grant: 1S10OD023586-01
Purchase of a Q Exactive HF mass spectrometer system for metabolomics
National Institutes of Health
Grant: 1S10OD021669-01A1
Purchase of a PerkinElmer IVIS SpectrumCT Imaging System
FWCI
0.84
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals